Optimizing conventional medical therapies in inflammatory bowel disease in 2014

Current Drug Targets

Volumn 15, Issue 11, 2014, Pages 1002-1010

  Asthana, Anil Kumar ^a   Sparrow, Miles P ^a   Peyrin Biroulet, Laurent ^b  

^a ALFRED HOSPITAL   (Australia)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Allopurinol; Aminosalicylates; Anti tumor necrosis factor agents; Corticosteroids; Therapeutic drug monitoring; Thioguanine nucleotides; Thiopurines

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; ALLOPURINOL; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE DERIVATIVE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID DERIVATIVE; DRUG METABOLITE; GLUCOCORTICOID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHOTREXATE DERIVATIVE; PREDNISOLONE; THIOGUANINE DERIVATIVE; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; HUMAN; INFLAMMATORY BOWEL DISEASE; LEUKOPENIA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84922384011     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140915113503     Document Type: Article

References (70)

1. Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106(4): 601-16.
2. Kruis W, Kiudelis G, Racz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double blind, double-dummy, randomised, non-inferiority trial. Gut 2009; 58(2): 233-40.
3. Zhu Y, Tang RK, Zhao P, Zhu SS, Li YG, Li JB. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2012; 24(5): 487-94.
4. Tong JL, Huang ML, Xu XT, Qiao YQ, Ran ZH. Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis. J Dig Dis 2012; 13(4): 200-7.
5. Gandia P, Idier I, Houin G. Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers. J Clin Pharmacol 2007; 47(3): 334-42.
6. Hussain FN, Ajjan RA, Kapur K, Moustafa M, Riley SA. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther 2001; 15(1): 53-62.
7. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4. 8 g/day (800 mg tablets) compared to 2. 4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol 2007; 21(12): 827-34.
8. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4. 8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100(11): 2478-85.
9. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4. 8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009; 137(6): 1934-43 e1-3.
10. Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 1996; 31(3): 260-6.
11. Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMX. Inflamm Bowel Dis 2005; 11(5): 421-7.
12. Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007; 26(2): 205-15.
13. Kane S, Katz S, Jamal MM, et al. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. Inflamm Bowel Dis 2012; 18(6): 1026-33.
14. Williams C, Panaccione R, Ghosh S, Rioux K. Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol 2011; 4(4): 237-48.
15. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92(10): 1867-71.
16. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54(7): 960-5.
17. Ford AC, Khan KJ, Achkar JP, Moayyedi P. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. Am J Gastroenterol 2012; 107(2): 167-76; author reply 77.
18. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ 1955; 2(4947): 1041-8.
19. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012; 61(11): 1619-35.
20. Rutgeerts PJ. Review article: the limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 2001; 15(10): 1515-25.
21. Prantera C, Marconi S. Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity. Therap Adv Gastroenterol 2013; 6(2): 137-56.
22. Rhodes JM, Robinson R, Beales I, et al. Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis. Aliment Pharmacol Ther 2008; 27(3): 228-40.
23. De Iudicibus S, Lucafo M, Martelossi S, Pierobon C, Ventura A, Decorti G. MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases. WJG 2013; 19(44): 7947-54.
24. Benchimol EI, Seow CH, Otley AR, Steinhart AH. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009(1): CD002913.
25. Papi C, Luchetti R, Gili L, Montanti S, Koch M, Capurso L. Budesonide in the treatment of Crohn's disease: a meta-analysis. Aliment Pharmacol Ther 2000; 14(11): 1419-28.
26. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. The Am J Gastroenterol 2011; 106(4): 590-9; quiz 600.
27. Fasci Spurio F, Aratari A, Margagnoni G, Clemente V, Moretti A, Papi C. Low bioavailability and traditional systemic steroids in IBD: can the former take over the latter? J Gastro and Liver Dis: JGLD 2013; 22(1): 65-71.
28. Gionchetti P, Rizzello F, Poggioli G, et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 2007; 25(10): 1231-6.
29. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. NEJM 2012; 367(16): 1519-28.
30. Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63(3): 433-41.
31. Gionchetti P, Calabrese C, Calafiore A, et al. Oral beclomethasone dipropionate in chronic refractory pouchitis. J Crohn's & Colitis 2014; 8(7): 649-53.
32. Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 9: CD000478.
33. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. The Cochrane Database of Systematic Rev 2009(1): CD000067.
34. Chatu S, Subramanian V, Saxena S, Pollok RC. The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109(1): 23-34; quiz 5.
35. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009; 104(8): 2089-96.
36. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. NEJM 2010; 362(15): 1383-95.
37. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146(2): 392-400 e3.
38. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130(4): 1047-53.
39. Moreau AC, Paul S, Del Tedesco E, et al. Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis. Inflamm Bowel Dis 2014; 20(3): 464-71.
40. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118(4): 705-13.
41. Gonzalez-Lama Y, Bermejo F, Lopez-Sanroman A, et al. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther 2011; 34(5): 544-54.
42. Dassopoulos T, Dubinsky MC, Bentsen JL, et al. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther 2014; 39(2): 163-75.
43. Haines ML, Ajlouni Y, Irving PM, et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011; 17(6): 1301-7.
44. Kennedy NA, Asser TL, Mountifield RE, Doogue MP, Andrews JM, Bampton PA. Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease. IMJ 2013; 43(3): 278-86.
45. Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol 2008; 103(12): 3115-22.
46. de Boer NK, Wong DR, Jharap B, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007; 102(12): 2747-53.
47. de Graaf P, de Boer NK, Wong DR, et al. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy. Br J Pharmacol 2010; 160(5): 1083-91.
48. Nguyen TM, Le Gall C, Lachaux A, Boulieu R. High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine. J Clin Pharmacol Ther 2010; 48(4): 275-81.
49. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005; 22(5): 441-6.
50. Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2013; 19(2): 363-9.
51. Kennedy NA, Rhatigan E, Arnott ID, et al. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Aliment Pharmacol Ther 2013; 38(10): 1255-66.
52. Seinen ML, van Asseldonk DP, Mulder CJ, de Boer NK. Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice. JGLD 2010; 19(3): 291-4.
53. Ansari A, Patel N, Sanderson J, O'Donohue J, Duley JA, Florin TH. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31(6): 640-7.
54. Smith MA, Blaker P, Marinaki AM, Anderson SH, Irving PM, Sanderson JD. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohn's & Colitis 2012; 6(9): 905-12.
55. Wilson A, Patel V, Chande N, et al. Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 2013; 37(3): 340-5.
56. de Rotte MC, den Boer E, de Jong PH, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Annals Rheum Dis 2013.
57. Bulatovic Calasan M, den Boer E, de Rotte MC, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients. Annals Rheum Dis 2013 [Epub ahead of print].
58. Brooks AJ, Begg EJ, Zhang M, Frampton CM, Barclay ML. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Therap Drug Monitoring 2007; 29(5): 619-25.
59. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol & Hepatol 2008; 6(6): 644-53.
60. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. NEJM 2003; 348(7): 601-8.
61. Ben-Bassat Oea. Association of serum infliximab and antibodies to infliximab to long-term clinical outcome and mucosal healing in Crohn's disease. Gastroenterology May 2013; 144(5): 775.
62. Van Moerkercke W, Ackaert C, Compernolle G, et al. High infliximab trough levels are associated with mucosal healing in Crohn's disease. Gastroenterology 2010; 138(5): 60. 2010.
63. Cornillie F, Hanauer SB, Diamond RH, et al. Early serum infliximab trough level, clinical disease activity and CRP as markers of sustained benefit of infliximab treatment in Crohn's disease: a post-hoc analysis of the ACCENT 1 trial. Am J Gastroenterol 2011; 106: S462-3.
64. Feagan BG, Singh S, Lockton S, et al. Novel infliximab and antibody-to-infliximab assays are predictive of disease activity in patients with Crohn's disease. Gastroenterology 2012; 142: S114.
65. Vande Casteele N, Compernolle G, Ballet V, et al. Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the TAXIT study. United European Gastroenterology Journal 2013; 1(1): OP001.
66. Velayos F, Sheibani S, Lockton S, et al. Prevalence of antibodies to adalimumab (ATA) and correlation between ATA and low serum drug concentration on CRP and clinical symptoms in a prospective sample of IBD patients. Gastroenterology 2013; 144(5): 91.
67. Mazor Y, Koplov U, Ben Hur D, et al. Evaluating adalimumab drug and antibody levels as predictors of clinical and laboratory response in Crohn's disease patients. Gastroenterology 2013; 144(5): 778.
68. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137(5): 1628-40.
69. Colombel JF, Sandborn WJ, Allez M, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol 2014; 12(3): 423-31 e1.
70. Afif W, Loftus EV, Jr., Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105(5): 1133-9.